Results 21 to 30 of about 70,538 (300)

Subcutaneous IgG Replacement Therapy by Push in 32 Patients with Primary Immunodeficiency Diseases in Argentine [PDF]

, 2014
Introduction: Regular replacement with immunoglobulin infusions is the mainstay of treatment in the majority of primary immunodeficiencies. Several studies showed that Subcutaneous Immunoglobulin (SCIG) has similar efficacy to Intravenous Immunoglobulin (
Bezrodnik, Liliana, Díaz Ballve, Damacia, Giovanni, Daniela Di, Gómez Raccio, Andrea, Moreira, Ileana, Regairaz, Lorena, Seminario, Gisela   +6 more
core   +1 more source

Human inmmunoglobulin in primary immunodeficiencies

Acta Pediátrica de México, 2014
Human immunoglobulin replacement therapy has become a corner- stone in the treatment of patients with primary immunodeficiencies (PID). Currently indicated as first-line therapy for predominantly antibody deficiencies, severe combined immunodeficiencies,
Sheffler Mendoza Selma, Partida Gaytán Armando, Yamazaki Nakashimada Marco Antonio   +2 more
doaj   +1 more source

Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review [PDF]

, 2014
BACKGROUND: Intravenous (IV) drug delivery is commonly used for its rapid administration and immediate drug effect. Most studies compare IV to subcutaneous (SC) delivery in terms of safety and efficacy, but little is known about what patients prefer.
Fallowfield, Lesley J, Harder, Helena, Jenkins, Valerie A, Stoner, Kelly L   +3 more
core   +1 more source

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E [PDF]

, 2020
Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising ...
Biedermann, Paula, Bock, Claus-Thomas, Choi, Mira, Hanitsch, Leif Gunnar, Hofmann, Jörg, Mueller, Tobias, Schulz, Marten, Tacke, Frank   +7 more
core   +1 more source

Successful discontinuation of immunoglobulin G replacement at age 10 in a patient with immunoglobulin G2 deficiency

SAGE Open Medical Case Reports, 2017
Context: Immunoglobulin G2 deficiency that persists beyond the age of 6 years is likely to be permanent. Case report: We report on a young Japanese female, diagnosed as having immunoglobulin G2 deficiency and low anti-pneumococcal immunoglobulin G2 ...
Masayoshi Shinjoh, Yukio Sakiyama, Shinichiro Sekiguchi, Takao Takahashi   +3 more
doaj   +1 more source

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease

Frontiers in Immunology, 2021
ObjectiveTo evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement therapy.MethodsPatients ...
Joanna Tieu, Joanna Tieu, Joanna Tieu, Rona M. Smith, Rona M. Smith, Seerapani Gopaluni, Seerapani Gopaluni, Dinakantha S. Kumararatne, Mark McClure, Mark McClure, Ania Manson, Sally Houghton, David R. W. Jayne, David R. W. Jayne   +13 more
doaj   +1 more source

Intravenous Immunoglobulins: Mechanism of Action and Limitations of Clinical Application in Pediatrics

Zdorovʹe Rebenka, 2016
This review deals with an analysis of the available clinical studies and reports concerning the evaluation of the effectiveness and safety of intravenous immunoglobulins (IVIG) in various diseases in children. Intravenous immunoglobulins are drugs with a
S.O. Mokiia-Serbina
doaj   +1 more source

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury. a Case Series [PDF]

, 2018
Background/Aims: Multiple myeloma (MM) represents 10% of all haematologic malignancies. Renal involvement occurs in 50% of MM patients; of them, 12-20% have acute kidney injury (AKI), with 10% needing dialysis at presentation. While hemodialysis (HD) has
Antolino, Giusy, Festuccia, Francescaromana, Fofi, Claudia, Giammarioli, Elisa, La Verde, Giacinto, Mene, Paolo, Punzo, Giorgio, Tafuri, Agostino   +7 more
core   +2 more sources

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials [PDF]

, 2018
Background: This study assessed the immunogenicity of pegvaliase (recombinant Anabaena variabilis phenylalanine [Phe] ammonia lyase [PAL] conjugated with polyethylene glycol [PEG]) treatment in adults with phenylketonuria (PKU) and its impact on safety ...
Atkinson, John P, Boyer, Ryan, Gu, Zhonghu, Gupta, Soumi, Harding, Cary O, Knight, Vijaya, Larimore, Kevin, Lau, Kelly, Li, Mingjin, Olbertz, Joy, Rosen, Orli, Shepherd, Gillian, Shweighardt, Becky, Weng, Haoling H, Zoog, Stephen J   +14 more
core   +2 more sources

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

Haematologica, 2014
Intravenous immunoglobulin replacement therapy represents the standard treatment for hypogammaglobulinemia secondary to B-cell lymphoproliferative disorders. Subcutaneous immunoglobulin infusion is an effective, safe and well-tolerated treatment approach
Nicolò Compagno, Francesco Cinetto, Gianpietro Semenzato, Carlo Agostini   +3 more
doaj   +1 more source